Immune response to mRNA COVID-19 vaccine given at the same time or after flu shots: a randomized trial

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Emmanuel B. Walter, et al. reports financial support was provided by Duke University Human Vaccine Institute. Emmanuel Walter et al. reports a relationship with Duke University Human Vaccine Institute that includes: funding grants. EBW has received support from Pfizer, Moderna, Seqirus, Najit Technologies and Clinetic as an investigator for clinical trials or studies. He has served as an advisor to Vaxcyte, Seqirus, and Pfizer, consultant to Iliad Biotechnologies and data safety monitoring board member for Shionogi and Emmes. EPS has received support from Pfizer for clinical trials and has served as an advisor for Sanofi Pasteur. MAS has received support from Pfizer for clinical trials. The Schubert Research Center at CCHMC is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health, under award number 5UL1TR001425-04. KRT has received support from Pfizer, Sanofi, and Scandinavian Biopharma as an investigator for clinical trials, serves on Safety Monitoring Committees for Merck, Takeda, and Moderna, and as an advisor for Intralytix. KES also received support from the National Institute on Aging, Duke Pepper Older Americans Independence Center, NIA P30AG028716. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The other authors have nothing to disclose. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.